Axiom Biosciences Targets 2027 Hong Kong IPO as Hang Seng Biotech Index Jumps 75%
Updated
Updated · CNBC · Jul 21
Axiom Biosciences Targets 2027 Hong Kong IPO as Hang Seng Biotech Index Jumps 75%
3 articles · Updated · CNBC · Jul 21
Summary
Axiom Biosciences plans to go public in Hong Kong in 2027 and pursue a secondary U.S. listing in 2029, an unusual route for a San Diego biotech that says Asia can speed funding and partnerships.
Hong Kong’s appeal rests on a tougher private fundraising climate and stronger biotech market momentum: the Hang Seng Biotech Index has risen more than 75% since January 2025, outpacing roughly 40%-50% gains in key U.S. biotech indexes.
Axiom’s CEO said the city offers sophisticated biotech investors and closer access to Asian clinical and commercial partners, while stricter listing rules signal a more mature biotech ecosystem.
The company is co-developing a therapy for severe newborn brain injuries with South Korea’s Medinno; a Phase 1 trial in nine newborns has been completed, and Axiom also wants to test the treatment in stroke patients.
The plan comes as Hong Kong builds biotech fundraising clout with more than 70 sector listings and faster IPO rules, even as investors still tend to favor companies with a clear China connection and the U.S. remains biotech’s deepest capital market.
Can a US company succeed by listing in Hong Kong amid growing American restrictions on China's biotech industry?
With private funding 'broken,' will Hong Kong's public market become the new lifeline for small American biotech firms?
Axiom Biosciences to Pioneer 2027 Hong Kong IPO: Implications for U.S. Biotech and Asian Markets
Overview
Axiom Biosciences, a San Diego-based biotech company founded in 2018 and formerly known as Cytonus Therapeutics, is planning a landmark Hong Kong IPO in 2027. This move highlights the company's commitment to developing next-generation regenerative therapies and targeted biologics using advanced cellular engineering. By targeting challenging diseases in neurology and beyond, Axiom is building a robust pipeline of innovative treatments. The planned IPO not only marks a significant step for Axiom but also signals the growing appeal of Hong Kong as a global hub for biotech fundraising, reflecting broader trends in the international life sciences sector.